Gisèle Deblandre joins Cellbox Solutions as CSO

05.10.2021 - Pirmin Fuchs
Cellbox Solutions GmbH has recruited Dr. Gisèle Deblandre to the team. The well-known industry expert joins the biotechnology company as Chief Scientific Officer (CSO) effective today. With her extensive knowledge in the development of manufacturing processes and analytical methods for cell-based therapies and ex-vivo gene therapies, Deblandre will be responsible for the Cell & Gene Therapy division and successfully develop this market for Cellbox Solutions. In addition, her responsibilities as CSO include the organization and implementation of further scientific projects.

The Belgian native brings decades of experience in molecular cell biology, developmental biology and related project management. For the past 20 years, Deblandre has also been responsible for team management in various disciplines of regenerative medicine. Most recently, Deblandre was Head of Science and Technology at CATALENT Cell Therapy. Prior to that, she served as Chief Scientific Officer at MaSTherCell. She holds a PhD in Molecular Cell Biology from the University of Brussels in Belgium.

"Gisèle Deblandre is a known name in the industry. Therefore, we are very proud to welcome her to the Cellbox Solutions team," says Prof. Dr. Kathrin Adlkofer, COO and founder of Cellbox Solutions. "As CSO in our company, Gisèle can combine her comprehensive knowledge and extensive experience to successfully establish the Cellbox in the field of Cell & Gene Therapy.”

Wolfgang Kintzel, CEO of Cellbox Solutions, adds “With Gisèle on board, we strengthen our international team and with her expertise, we will push the topic of Live Cell Transport in the field of Cell Therapy. Our technologies facilitate the development of new therapies and provide our customers wider access for patients worldwide.”